BeyondSpring (BYSI) Operating Income (2016 - 2026)
BeyondSpring (BYSI) posted Operating Income of -$2.2 million for Q1 2026, up 14.02% sequentially from -$2.6 million in Q4 2025, and up 14.48% YoY from -$1.9 million in Q1 2025.
BeyondSpring (BYSI) Operating Income (2016 - 2026) Analysis & Trends
BeyondSpring has reported Operating Income for 9 years, with the latest figure at -$2.2 million in Q1 2026.
- Quarterly Operating Income rose 14.48% year-over-year to -$2.2 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$8.6 million (up 7.97% YoY) and the FY2025 annual result came in at -$8.9 million, down 2.18% from the prior year.
- Operating Income improved to -$2.2 million in Q1 2026 per BYSI's latest filing, from -$2.6 million in the prior quarter.
- Over five years, Operating Income peaked at -$1.7 million in Q4 2024 and troughed at -$2.6 million in Q2 2024.
- A 3-year average of -$2.2 million and a median of -$2.2 million in 2026 frame the typical range for Operating Income.
- The widest YoY moves for Operating Income: up 26.2% in 2025, down 52.71% in 2025.
- Over 3 years, Operating Income stood at -$1.7 million in 2024, then plunged by 52.71% to -$2.6 million in 2025, then increased by 14.02% to -$2.2 million in 2026.
- According to Business Quant data, Operating Income over the past three periods registered -$2.2 million, -$2.6 million, and -$1.8 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Op. Inc (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn | 1.25 Bn |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn | 1.29 Bn |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn | 493.00 Mn |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn | -815.00 Mn |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn | 325.05 Mn |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn | 231.44 Mn |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn | -1.55 Mn |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - | 133.12 Mn |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn | -375.75 Mn |
| 10 | BeyondSpring | 30.22 Mn | 30.22 Mn | - | -1.73 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -1.73 Mn |
| Mar 31, 2026 | -2.23 Mn |
| Dec 31, 2025 | -2.60 Mn |
| Sep 30, 2025 | -1.79 Mn |
| Jun 30, 2025 | -1.95 Mn |
| Mar 31, 2025 | -2.61 Mn |
| Dec 31, 2024 | -1.70 Mn |
| Sep 30, 2024 | -2.36 Mn |
| Jun 30, 2024 | -2.64 Mn |
| Mar 31, 2024 | -2.06 Mn |
| Dec 31, 2021 | -10.49 Mn |
| Sep 30, 2021 | -18.35 Mn |
| Jun 30, 2021 | -19.98 Mn |
| Mar 31, 2021 | -17.42 Mn |
| Dec 31, 2020 | -18.62 Mn |
| Sep 30, 2020 | -15.35 Mn |
| Jun 30, 2020 | -13.62 Mn |
| Mar 31, 2020 | -16.63 Mn |
| Dec 31, 2019 | -15.29 Mn |
| Sep 30, 2019 | -9.70 Mn |